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ABSTRACT
Introduction: Patients with neurosyphilis may present with severe neuropsychiatric sequelae which do not respond adequate-
ly even to clozapine which is regarded as the most efficacious medication for the treatment of schizophrenia. Clozapine augmen-
tation with electroconvulsive therapy (ECT) has been shown to be an effective and safe treatment strategy for treatment-resis-
tant schizophrenia.
Objective: This case report aimed to describe a patient with neurosyphilis, whose psychotic symptoms did not improve sig-
nificantly although he had multiple adequate medication trials including daily doses of fluoxetine 40 mg, olanzapine 15 mg, hal-
operidol 15 mg, sulpiride 1,000 mg, quetiapine 800 mg, and finally clozapine 150 mg. 
Result: The patient was stabilized with a combination of clozapine and maintenance ECT. A total of no less than 120 sessions 
of ECT (stimulus dose ranged 15-200% and seizure duration 8-57 seconds) were given by August 2017 while the clozapine was 
maintained at 75 mg bd. The patient had one episode of spontaneous seizure during induction of general anesthesia with etomi-
date. Otherwise, there was no documented serious adverse effect.
Conclusion: Maintenance electroconvulsive therapy augmentation on clozapine-resistant psychosis with neurosyphilis is 
effective and safe but has never been reported in the literature to the authors' knowledge. It is hoped that this case report would 
contribute to the scarce literature on this augmentation strategy.
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The malarial pyrotherapy for general paresis of the insane was a 
groundbreaking discovery in the treatment of what is now more com-
monly referred to as neurosyphilis1). Pyrotherapy soon fell out of favor 
with the discovery of penicillin for the treatment of syphilis, which 
coincided with the advent of convulsive therapy for psychotic disorders. 
In 1943, a study described the use of "electric shock" ranging 2-7 times 
in 5 patients who had completed malaria therapy. The therapeutic value 
was inconclusive as all patients had persistent psychotic symptoms and 
developed serious adverse effects associated with the treatment2). 
Solomon et al in 1948 reported 5 cases and discussed the benefits and 
limitations of electric shock in the psychoses of general paresis3). 
Vilanova et al reported improvement of pain, incontinence, and ataxia in 
a patient who developed tabes dorsalis with severe neurological symp-
toms, despite 5 years of treatment for syphilis with arsenic, bismuth, 
mercury, and penicillin4). 
Subsequent reports clearly demonstrated the therapeutic value of 
electroconvulsive therapy (ECT) in neurosyphlis, despite the initial set-
backs due to severe adverse effects. The ECT demonstrated a calming 
effect for uncontrollable mania in 6 patients with general paresis of the 
insane5). Another case report described a 67-year-old man with neu-
rosyphilis who developed signs of depression and psychotic symptoms 
after he was treated with penicillin. The ECT substantially improved the 
psychotic symptoms with long-term positive effects, after inadequate 
response to haloperidol titrated up to 50 mg/day6). In a recent case 
report, a 40-year-old man newly diagnosed with neurosyphilis during 
hospitalization for a psychotic state with depression responded to 8 ses-
sions of ECT that rapidly relieved the psychotic symptoms after failure 
to respond to several type of antipsychotics7). 
Nevertheless in this era of widely available penicillin and effective 
psychopharmacological agents, there exist subgroups of patients with 
neurosyphilis who fail to adequately respond to treatment. Allen et al 
reported a patient whose symptoms did not improve significantly 
although he had multiple adequate medication trials including daily 
dose of haloperidol 5 mg, citalopram 20 mg, donepezil 5 mg, oxcarba-
zepine 450 mg, olanzapine 20 mg, memantine 10 mg, carbamazepine 
400 mg, and finally clozapine 200 mg8).
A strategy that can be useful in treating poor prognosis neurosyphi-
lis is augmentation of clozapine with ECT. It has been used in clozap-
ine-resistant schizophrenia9-12), albeit concerns about the side-effects like 
prolonged seizures and tachycardia. Despite increased risk of clozap-
ine-related side-effects13,14), limited evidence from a randomized con-
trolled trial and open-label trials suggest that ECT is an effective inter-
vention in clozapine-refractory schizophrenia15). A systematic review 
and meta-analysis of retrospective chart reviews, case series and case 
reports involving 192 patients treated with clozapine and ECT indicated 
and overall response of 66% and adverse effects in 14% of them16).
There were few case reports on neurosyphilis with psychosis in 
Malaysia.17-19) However, only the short-term treatment with antibiotics 
and antipsychotics was described, and none of them were treated with 
either ECT or clozapine. Similarly, the authors could not find in the lit-
erature any previous report on the combined use of ECT and clozapine 
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for the treatment of neurosyphilis. Thus, the aim of this case report is to 
illustrate the ECT augmentation on clozapine-resistant psychosis due to 
neurosyphilis. 
CASE  REPORT
A 54-year-old divorced, unemployed gentleman with history of pro-
miscuity in his youth first presented to us seven years ago with auditory 
hallucinations, persecutory delusions, disorganized behavior and neuro-
logical symptoms including unstable gait, myoclonic jerk, and intention-
al tremors. The TPHA was positive with VDRL titer of 1:16. Brain MRI 
showed left temporal gliosis. He was diagnosed as schizophrenia-like 
psychosis secondary to neurosyphilis. He was treated with intramuscu-
lar benzylpenicillin 2.4 mega unit weekly for 3 weeks, and the VDRL 
titer was reduced to 1:8. In February 2017, he was treated with intrave-
nous penicillin 4 mega unit 4 hourly for 2 weeks as patient developed 
reactivation of neurosyphilis evidenced by the raised VDRL titer to 
1:16.
The patient was treated with psychotropic agents such as fluoxetine, 
olanzapine and haloperidol up to daily dose of 40 mg, 15 mg and 15 mg, 
respectively. He developed tremors, oversedation on olanzapine and 
serious adverse effect, neuroleptic malignant syndrome (NMS) while on 
haloperidol. Afterward, he was tried on paliperidone (highest dose 150 
mg monthly), sulpiride (highest dose 1,000 mg daily) and quetiapine 
(highest dose 800 mg daily), but showed poor to no response despite 
adequate dosage and duration of treatment. The case was regarded as a 
treatment-resistant psychosis due to neurosyphilis and clozapine was 
started. The patient was able to tolerate only up to 150 mg of clozapine 
daily as he developed constipation on higher dose.
A year after the initial presentation, ECT as augmentation strategy 
was initiated while clozapine was continued at 75 mg bd. The ECT was 
extended to maintenance treatment fortnightly and later the interval was 
shortened to every 10 days as he developed psychosis before the next 
maintenance ECT sessions. As of August 2017, the patient had under-
gone not less than 120 sessions of ECT. The stimulus dosage ranged 
15-200% and the seizure duration 8-57 seconds. Thymatron® System 
IV which is capable of delivering electrical stimulus 504 mC at 100% 
was used. The patient had one episode of seizures that occurred during 
induction of general anesthesia with etomidate. Otherwise, there was no 
other serious adverse effect documented. Although patient still had 
occasional episodes of relapse due to non-compliance to ECT, but gen-
erally, he was maintaining relatively well and manageable with the com-
bination of clozapine and maintenance ECT. 
DISCUSSION
This case illustrates the difficulties in treating the psychiatric 
sequelae of neurosyphilis. Due to irreversible neuronal loss, success of 
treatment depends on early diagnosis. Failure to diagnose neurosyphilis 
was associated with prolonged psychosis that has been refractory to 
antipsychotic treatment20). In this case, irreversible parenchymal neurons 
damage and ongoing infectious process were indicated by left temporal 
gliosis and reactivation of infection in 2017, respectively. This is similar 
to a case report, in which the refractory psychiatric symptoms were 
thought to stem from an ongoing infectious process despite appropriate 
antibiotics treatment, or irreversible brain damage evidenced by cerebral 
atrophy, despite resolution of the central nervous system infection8). 
Another potential insult to the brain was the NMS as brain atrophy was 
reported following a refractory and complicated NMS21).
During the course of illness, the symptoms were noted to be 
increasingly difficult to control until the patient was initiated on clozap-
ine trial. The ECT augmentation was initially given as acute treatment, 
and later was extended as maintenance treatment with interval progres-
sively shortened from fortnightly to every 10 days. This case also illus-
trates the safety of the combined use of ECT and clozapine. The patient 
did not develop any serious adverse effects. Nevertheless, the clinician 
must always be alert for sign of adverse effect such as myocarditis and 
pericarditis which can develop in older patient treated with clozapine22). 
Antipsychotics including clozapine can induced metabolic syndrome 
that increase the mortality risk23), particularly since ECT itself causes 
significant hemodynamic changes.
CONCLUSION
The ECT was indicated in a patient with neurosyphilis and psycho-
sis who responded inadequately to psychopharmacological agents 
including clozapine. Although the infection was controlled by intensive 
treatment with penicillin, neurosyphilis was still associated with severe 
psychotic symptoms. Augmentation of clozapine with maintenance ECT 
is effective and safe in patient with neurosyphilis with severe psychotic 
symptoms. It is hoped that this case report would contribute to the 
scarce literature on the combine use of ECT and clozapine, which is 
important for the development of guidelines and recommendations for 
the treatment of severe psychiatric complications of neurosyphilis.
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